These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 14703602)

  • 1. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis.
    Aki S; Eskiyurt N; Akarirmak U; Tüzün F; Eryavuz M; Alper S; Arpacioğlu O; Atalay F; Kavuncu V; Kokino S; Kuru O; Nas K; Ozerbil O; Savaş G; Sendur OF; Soy D; Akyüz G;
    Yonsei Med J; 2003 Dec; 44(6):961-7. PubMed ID: 14703602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
    Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J
    Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study.
    Eisman JA; Rizzoli R; Roman-Ivorra J; Lipschitz S; Verbruggen N; Gaines KA; Melton ME
    Curr Med Res Opin; 2004 May; 20(5):699-705. PubMed ID: 15140336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
    Bauer DC; Black D; Ensrud K; Thompson D; Hochberg M; Nevitt M; Musliner T; Freedholm D
    Arch Intern Med; 2000 Feb; 160(4):517-25. PubMed ID: 10695692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E; Lang A; Robbins S; Ström O
    Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
    Taggart H; Bolognese MA; Lindsay R; Ettinger MP; Mulder H; Josse RG; Roberts A; Zippel H; Adami S; Ernst TF; Stevens KP
    Mayo Clin Proc; 2002 Mar; 77(3):262-70. PubMed ID: 11888030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.
    Cryer B; Miller P; Petruschke RA; Chen E; Geba GP; Papp AE
    Aliment Pharmacol Ther; 2005 Mar; 21(5):599-607. PubMed ID: 15740544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
    Lanza F; Sahba B; Schwartz H; Winograd S; Torosis J; Quan H; Reyes R; Musliner T; Daifotis A; Leung A
    Am J Gastroenterol; 2002 Jan; 97(1):58-64. PubMed ID: 11808969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
    Ralston SH; Kou TD; Wick-Urban B; Steinbuch M; Masud T
    Calcif Tissue Int; 2010 Oct; 87(4):298-304. PubMed ID: 20803291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?
    Cryer B; Bauer DC
    Mayo Clin Proc; 2002 Oct; 77(10):1031-43. PubMed ID: 12374247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of mandatory generic substitution on the safety of alendronate and patients' adherence.
    Lai PS; Chua SS; Chong YH; Chan SP
    Curr Med Res Opin; 2012 Aug; 28(8):1347-55. PubMed ID: 22746354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
    Cheng TT; Yu SF; Hsu CY; Chen SH; Su BY; Yang TS
    Clin Ther; 2013 Jul; 35(7):1005-15. PubMed ID: 23831360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(1):20-33. PubMed ID: 12122976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
    J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of gastrointestinal symptoms at daily 10 mg versus weekly 70 mg Alendronate prescription in 195 osteoporotic cases.
    Amiri AH; Tarrahi MJ
    Indian J Med Sci; 2011 Nov; 65(11):482-7. PubMed ID: 23525025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compliance of osteoporotic patients with different treatment regimens.
    Segal E; Tamir A; Ish-Shalom S
    Isr Med Assoc J; 2003 Dec; 5(12):859-62. PubMed ID: 14689753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects.
    Sewell K; Schein JR
    Semin Arthritis Rheum; 2001 Feb; 30(4):288-97. PubMed ID: 11182029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.